ArticleBlood2011
Regulatory effects of TLR2 on megakaryocytic cell function.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 106 citations in OpenAlex.
- Inflammation in acute coronary syndrome: Expression of TLR2 mRNA is increased in platelets of patients with ACS.PloS one · 2019Trial
- Platelet WDR1 suppresses platelet activity and is associated with cardiovascular disease.Blood · 2016Trial
- Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026Review
- A pathogenic gut lipoglycan drives systemic thromboinflammation in lupus nephritis.Annals of the rheumatic diseases · 2026Article
- Pharmacogenomic impact and genetic architecture of toxicity in pediatric acute lymphoblastic leukemia induction therapy: an exploratory modeling approach.Frontiers in pharmacology · 2026Article
- Mature megakaryocytes acquire immune characteristics in a mouse model of aplastic anemia.Blood advances · 2025Article
- Regulating mitochondrial oxidative phosphorylation and MAPK signaling: wedelolactone as a novel therapeutic for radiation-induced thrombocytopenia.Frontiers in pharmacology · 2025Article
- Oxymatrine, a novel TLR2 agonist, promotes megakaryopoiesis and thrombopoiesis through the STING/NF-κB pathway.Journal of pharmaceutical analysis · 2025Article
- Immunological face of megakaryocytes.Frontiers of medicine · 2024Review
- Light-activated nanoclusters with tunable ROS for wound infection treatment.Bioactive materials · 2024Article
- Versatility of megakaryocytes in homeostasis and disease.Blood science (Baltimore, Md.) · 2024Review
- SARS-CoV-2 infection modifies the transcriptome of the megakaryocytes in the bone marrow.Blood advances · 2024Article
- Megakaryocytes in the lung: History and future perspectives.Research and practice in thrombosis and haemostasis · 2023Article
- Dissecting Platelet's Role in Viral Infection: A Double-Edged Effector of the Immune System.International journal of molecular sciences · 2023Review
- Toll-like Receptors and Thrombopoiesis.International journal of molecular sciences · 2023Review
- Megakaryocytes respond during sepsis and display innate immune cell behaviors.Frontiers in immunology · 2023Article
- Significance of TLR2 signaling during megakaryocyte development: regulatory cross-talk of miR-125b, cytokine induction, and MAPK pathway during dengue infection.American journal of translational research · 2023Article
- Targeting TLR2/Rac1/cdc42/JNK Pathway to Reveal That Ruxolitinib Promotes Thrombocytopoiesis.International journal of molecular sciences · 2022Article
- CXCR4eLife · 2022Article
- Neutrophil transit time and localization within the megakaryocyte define morphologically distinct forms of emperipolesis.Blood advances · 2022Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
TLR2, a functional, inflammatory-related receptor, is known to be expressed on megakaryocytes and platelets and to lead to infection and immune-mediated activation of platelets; however, the role of this receptor in megakaryocytes is not understood. Using Meg-01 cells and mouse megakaryocytes, we found that NFκB, ERK-MAPK, and PI3K/Akt pathways, known downstream pathways of TLRs, are activated by Pam3CSK4, a TLR2-specific ligand. In addition, transcription factors associated with megakaryocyte maturation, GATA-1, NF-E2, and mammalian target of rapamycin (mTOR), are all increased in the presence of Pam3CSK4. The effect of Pam3CSK4 on megakaryocyte maturation was verified by the increase in DNA content and adhesion to extracellular matrix proteins by TLR2-dependent stimulation. In addition, TLR2 stimulation resulted in an increase in reactive oxygen species (ROS) production. Gene expression and protein levels of GP1b, CD41, MCP-1, COX2, NFκB1, and TLR2 were up-regulated in megakaryocytes after TLR2 stimulation through NFκB, PI3K/Akt, and ERK-MAPK pathways. Treatment of wild-type mice with Pam3CSK4 resulted in a return to normal platelet levels and an increase in megakaryocyte maturation, which did not occur in the TLR2(-/-) mice. Therefore, inflammation, through TLR2, can increase maturation and modulate the phenotype of megakaryocytes, contributing to the interrelationship between inflammation and hemostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.